Avantor® Receives 2025 Edison Patent Award for Sustainable Viral Inactivation Technology
Research & Development Council of New Jersey honors Avantor for developing a biodegradable detergent solution that advances safe, sustainable biomanufacturing
RADNOR, Pa., Nov. 25, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced the Company, in partnership with Amgen, received a 2025 Edison Patent Award from the Research & Development Council of New Jersey. The recognition was for their pioneering development of a biodegradable detergent that enables safer, more sustainable viral inactivation in biomanufacturing.
Co-developed by Avantor and Amgen, Avantor's detergent delivers effective viral inactivation while maintaining protein integrity and increasing process yield. This jointly developed technology addresses a critical industry challenge by providing a compliant, high-performing, and environmentally responsible alternative for producing monoclonal antibodies, vaccines, and gene therapies.
"We are honored to be recognized by the R&D Council of New Jersey for this achievement," said Benoit Gourdier, Executive Vice President, Bioscience Production, Avantor. "Our collaboration demonstrates how strategic partnerships can drive scientific innovation and environmental responsibility to advance biomanufacturing. By developing safer, more effective detergents, Avantor is supporting our customers in producing vital therapies responsibly and with less impact on the environment."
Co-developed at Avantor's Bridgewater Innovation Center, this work strengthens Avantor's leadership in sustainable bioprocessing while showcasing the power of industry collaboration. The partnership also reinforces New Jersey's position as a global hub for scientific innovation and sustainable technology.
Read more about how Avantor developed J.T.Baker Viral Inactivation here.
About Avantor
Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.
Avantor Media Contact
Eric Van Zanten
Head of External Communications
610-529-6219
Eric.Vanzanten@avantorsciences.com
Avantor Investor Relations Contact
Allison Hosak
Senior Vice President, Global Communications
908-329-7281
Allison.Hosak@avantorsciences.com
View original content:https://www.prnewswire.com/news-releases/avantor-receives-2025-edison-patent-award-for-sustainable-viral-inactivation-technology-302624676.html
SOURCE Avantor and Financial News
Für dich aus unserer Redaktion zusammengestellt
Dein Kommentar zum Artikel im Forum
Jetzt anmelden und diskutieren
Registrieren
Login
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.